Kristie McNealy, MD

Ever since Synagis (aka palivizumab) was brought to market by MedImmune, there has been debate over which babies should benefit from its RSV protection, and which should not. Synagis has been shown to reduce RSV related hospitalizations by 50%, it hasn’t been shown to reduce RSV related deaths, and while it is believed that [...]